Core Insights - The company is currently conducting pivotal studies for daraxonrasib, with significant developments expected in the near future [1] - The most advanced registration study is the RASolute 302 trial for second-line pancreatic cancer, which is nearing completion of enrollment [2] - Promising Phase II data has been reported, and there is anticipation for the first registration data disclosure next year [2] Company Developments - The ongoing RASolute 302 trial is critical for the company's future, as it represents a key step towards potential market approval [2] - Efforts are being made to ensure that the positive outcomes from the Phase II study are effectively translated into the Phase III study [2]

Summary of Revolution Medicines FY Conference Call Company Overview - **Company**: Revolution Medicines (NasdaqGS:RVMD) - **Focus**: Development of daraxonrasib for pancreatic cancer and other RAS-driven cancers Key Points Industry and Product Development - **Ongoing Trials**: The company is conducting pivotal studies for daraxonrasib, particularly focusing on pancreatic cancer with the RESOLUTE 302 trial nearing completion of enrollment [1][2] - **Patient Population**: The phase one/two trial patient population is similar to those in phase three trials, with slightly worse prognostic factors, suggesting a representative sample for the upcoming phase three study [2] Trial Mechanics and Endpoints - **Primary Goal**: The main goal of the RESOLUTE 302 trial is to demonstrate an overall survival (OS) benefit, which is prioritized by the FDA for pancreatic cancer [4] - **Statistical Modeling**: The trial is powered for OS, with a high likelihood of reaching significance for progression-free survival (PFS) in interim analyses [5] - **Hierarchical Testing Strategy**: The trial will first evaluate the G12 mutation subset (85% of pancreatic cancer cases) before analyzing broader RAS mutation groups [6] Regulatory Designations - **Breakthrough Therapy Designation**: Daraxonrasib has received breakthrough therapy designation and orphan drug designation, which may accelerate the regulatory review process [9] - **Priority Review Voucher**: The company has received a priority review voucher, potentially allowing for a streamlined review process post-NDA filing [10] Future Trials and Strategies - **First-Line Pancreatic Cancer**: Plans to initiate the RESOLUTE 303 study, a three-arm trial comparing standard chemotherapy, daraxonrasib monotherapy, and daraxonrasib plus chemotherapy [11][12] - **Efficacy Data**: Phase one/two data showed promising overall response rates (ORR) of approximately 47% for monotherapy and 55% for combination therapy with gemcitabine [13] Treatment Paradigm - **RAS-Driven Cancers**: The underlying biology of pancreatic cancer is RAS-driven, leading to the design of trials that leverage effective RAS inhibitors [14] - **Patient-Centric Approach**: The company emphasizes providing multiple treatment options to cater to diverse patient needs and preferences [17][18] Other Cancer Studies - **Non-Small Cell Lung Cancer**: The RESOLVE 301 study is enrolling patients with any RAS mutation, targeting a significant portion of non-small cell lung cancer cases [25][26] - **Combination Therapies**: Plans to initiate a registration study in first-line non-small cell lung cancer combining daraxonrasib with chemotherapy and pembrolizumab [27][31] New Developments - **Zoldonrasib**: A RAS G12D-selective ON inhibitor is being developed, with potential applications in combination with daraxonrasib and aggressive chemotherapies [39][41] - **Clinical Strategy**: The company is exploring various combination regimens to maximize treatment efficacy for patients with RAS mutations [42] Additional Insights - **Market Positioning**: The company aims to differentiate its products in a competitive landscape by combining therapies that enhance patient outcomes [31][35] - **Long-Term Vision**: Revolution Medicines is focused on addressing unmet needs in RAS-driven cancers, with ongoing evaluations of its pipeline and potential new therapies [35][36]

Core Insights - Revolution Medicines (RVMD) reported a Q3 2025 loss of $1.61 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.39, and compared to a loss of 94 cents in the same quarter last year [1][9] - The company currently has no approved products and has not generated any revenue [1] - Year-to-date, RVMD shares have increased by 36%, outperforming the industry growth of 10% [1] Financial Performance - Research and development expenses reached approximately $263 million, reflecting a 73% year-over-year increase, primarily due to higher clinical study and manufacturing costs, as well as increased employee-related expenses [2] - General and administrative expenses were nearly $53 million, up 120% year-over-year, mainly driven by higher employee-related costs [2] - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $1.9 billion, down from $2.1 billion as of June 30, 2025 [3] Guidance - The company reiterated its full-year operating expenses guidance, expecting a range between $1.03 billion and $1.09 billion, which includes non-cash stock-based compensation expenses of $115-$130 million [4] Pipeline Developments - Revolution Medicines is developing multiple novel drugs targeting the active, GTP-bound form of RAS proteins, with daraxonrasib as the lead pipeline drug, designed to target major RAS mutation hotspots [5] - Daraxonrasib is currently being evaluated in two late-stage registrational studies: RASolve 301 for locally advanced or metastatic RAS-mutated NSCLC and RASolute 302 for second-line metastatic PDAC, with data readout from RASolute 302 expected in 2026 [6][9] - The company is expanding daraxonrasib's development in first-line settings for both NSCLC and PDAC, with studies expected to start before the end of 2025 and in 2026, respectively [7] - Additionally, RVMD is developing mutant-selective inhibitors like elironrasib and zoldonrasib, focusing on specific RAS mutations, and pursuing a combination strategy to enhance efficacy [8][10]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Financial Data and Key Metrics Changes - The company ended Q3 2025 with $1.93 billion in cash and investments, including a $250 million royalty monetization tranche received in June 2025, with an additional $1.75 billion in future committed capital under this arrangement [21] - R&D expenses for Q3 2025 were $262.5 million, up from $151.8 million in Q3 2024, primarily due to increased clinical trial-related and manufacturing expenses [21] - G&A expenses for Q3 2025 were $52.8 million, compared to $24.0 million in Q3 2024, driven by personnel-related expenses and increased commercial preparation activities [21] - The net loss for Q3 2025 was $305.2 million, compared to $156.3 million in Q3 2024, primarily due to higher operating expenses [22] - The company reiterated its 2025 financial guidance, expecting a full-year GAAP net loss between $1.03 billion and $1.09 billion [22] Business Line Data and Key Metrics Changes - Diraxonrasib has received three special designations from the FDA for its potential role in treating pancreatic cancer, including breakthrough therapy status and Orphan Drug designation [5][6] - The phase 3 trial, Resolute 302, for Diraxonrasib in second-line metastatic pancreatic cancer is nearing completion of enrollment, with data readout expected in 2026 [8] - Initial results for Diraxonrasib in first-line metastatic pancreatic cancer showed an objective response rate of 47% and a disease control rate of 89% [9] - The combination of Diraxonrasib with standard chemotherapy (GMP) demonstrated an objective response rate of 55% and a disease control rate of 90% [10] Market Data and Key Metrics Changes - The company is expanding its clinical programs in non-small cell lung cancer (NSCLC) and plans to initiate a registration trial in the first-line metastatic setting in 2026 [15] - Allieronrasib, a RAS-on G12C inhibitor, showed a confirmed objective response rate of 42% in heavily pretreated patients with G12C NSCLC [16] - The company is evaluating Zoledronrasib in a phase 1 monotherapy expansion cohort for previously treated NSCLC patients [17] Company Strategy and Development Direction - The company aims to build a leading global RAS-targeted medicines franchise, focusing on pancreatic, lung, and colorectal cancers [5] - The company is advancing its pipeline with multiple clinical trials, including the Resolute 303 trial for Diraxonrasib in first-line metastatic pancreatic cancer [10] - The company is exploring diverse combinations of RAS-on inhibitors with novel disease target inhibitors through collaborations [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of their RAS-on inhibitor portfolio to change standards of care across multiple cancer types [18] - The company is committed to understanding patient experiences with RAS-driven cancers and is expanding partnerships with advocacy organizations [24] - Management highlighted the importance of their strong financial position and expansive development plans to establish new global standards of care [23] Other Important Information - The company has made key appointments to strengthen its R&D and commercialization capabilities, including a new Chief Development Officer and regional leaders for the U.S. and European markets [19][20] Q&A Session Summary Question: Impact of FDA Commissioner's National Priority Voucher on Diraxonrasib timelines - Management indicated that the voucher could potentially shorten review timelines by one to two months and they are preparing for data readout and NDA submission [26] Question: Rationale for randomizing against observation in Resolute 304 trial - Management explained that requiring four months of standard care chemotherapy is to ensure uniformity in the patient population and to build upon the modest success seen with chemotherapy [32] Question: Expectations for phase 2 study results translating to phase 3 study - Management reassured that the patient populations in phase 1 and phase 3 studies are comparable, and they expect similar performance in the control arm [39] Question: Commercial readiness for Diraxonrasib - Management expressed confidence in their manufacturing capabilities and ongoing preparations for commercial launch readiness, including building a strong commercialization team [41] Question: Efficacy of combination treatment versus monotherapy - Management noted that both treatment strategies are being tested to evaluate their respective benefits, with updates expected in the first half of 2026 [46] Question: Commercial opportunity in the European Union - Management highlighted the significant patient population in Europe and their commitment to bringing Diraxonrasib to key markets [65] Question: Rationale for starting the adjuvant study before the first-line study - Management clarified that the adjuvant study is simpler and could be initiated earlier, without significant differences in overall conduct [70] Question: Resistance mechanisms in non-small cell lung cancer - Management indicated that data on resistance mechanisms in NSCLC is not yet mature for public disclosure, and the selection of pembrolizumab is based on its established role in standard care [76]

Financial Data and Key Metrics Changes - The company ended Q3 2025 with $1.93 billion in cash and investments, including a $250 million royalty monetization tranche received in June 2025, with an additional $1.75 billion in future committed capital [21] - R&D expenses for Q3 2025 were $262.5 million, up from $151.8 million in Q3 2024, primarily due to increased clinical trial-related and manufacturing expenses [21][22] - G&A expenses rose to $52.8 million in Q3 2025 from $24.0 million in Q3 2024, driven by personnel-related expenses and increased commercial preparation activities [22] - The net loss for Q3 2025 was $305.2 million, compared to $156.3 million in Q3 2024, attributed to higher operating expenses [22] Business Line Data and Key Metrics Changes - Diraxonrasib, a key product, received three special designations from the FDA, including breakthrough therapy status and Orphan Drug designation, highlighting its potential in treating pancreatic cancer [5][6] - The Phase III trial, Resolute 302, for Diraxonrasib in second-line metastatic pancreatic cancer is nearing completion of enrollment, with data readout expected in 2026 [8][10] - Initial results for Diraxonrasib in first-line metastatic pancreatic cancer showed an objective response rate of 47% and a disease control rate of 89% [8][9] Market Data and Key Metrics Changes - The company is expanding its clinical programs in non-small cell lung cancer (NSCLC) with ongoing trials for Diraxonrasib and Allieronrasib, targeting both previously treated and first-line settings [15][16] - The Resolve 301 registration trial for Diraxonrasib in NSCLC continues to enroll patients in the U.S., Europe, and Japan [15] Company Strategy and Development Direction - The company aims to build a leading global franchise for RAS-targeted medicines, focusing on pancreatic, lung, and colorectal cancers [5][23] - Plans to initiate a registration trial for Zoledronrasib in combination with Diraxonrasib in first-line metastatic pancreatic cancer are set for the first half of 2026 [14] - The company is enhancing its commercialization capabilities with new key appointments in the U.S. and European regions [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of their RAS-on inhibitor portfolio to change standards of care across multiple cancer types [18] - The company is committed to understanding patient experiences with RAS-driven cancers and is expanding partnerships with advocacy organizations [23] Other Important Information - The company reiterated its 2025 financial guidance, expecting a full-year GAAP net loss between $1.03 billion and $1.09 billion [22] - The company is on track to initiate the first-in-human trial for RMC 5127, an oral tri-complex RAS-on G12V selective inhibitor, in Q1 2026 [18] Q&A Session Summary Question: Impact of FDA Commissioner's National Priority Voucher on Diraxonrasib timelines - Management noted that the voucher could potentially shorten review timelines by one to two months and they are preparing for an NDA submission [26] Question: Rationale for randomizing against observation in Resolute 304 - Management explained that requiring four months of standard care chemotherapy is to ensure uniformity in the patient population and to build upon the modest success seen with chemotherapy [29][32] Question: Differences in patient characteristics between Phase II and Phase III studies - Management reassured that the patient populations in Phase I and Phase III studies are comparable, with historical data supporting this [36][39] Question: Commercial readiness for Diraxonrasib - Management highlighted strong manufacturing capabilities and ongoing efforts to build a talented commercialization team to ensure launch readiness [40][41] Question: Efficacy expectations for combination treatment versus monotherapy - Management indicated that both treatment strategies are being tested to evaluate their respective benefits, with updates expected in the first half of 2026 [44][46] Question: Commercial opportunity in the European Union - Management emphasized the significant patient population in Europe and the compelling value proposition for Diraxonrasib in the second-line pancreatic cancer indication [63][65] Question: Rationale for starting the adjuvant study before the first-line study - Management clarified that the adjuvant study is simpler and could be initiated earlier, without significant implications for overall conduct [68][70] Question: Resistance mechanisms in non-small cell lung cancer - Management stated that data on resistance mechanisms in NSCLC is not yet mature enough for public disclosure, and the selection of pembrolizumab is based on its established role in standard care [73][76]

Financial Data and Key Metrics Changes - The company ended Q3 2025 with $1.93 billion in cash and investments, including a $250 million royalty monetization tranche received in June 2025, with an additional $1.75 billion in future committed capital under this arrangement [21][22] - R&D expenses for Q3 2025 were $262.5 million, up from $151.8 million in Q3 2024, primarily due to increased clinical trial-related and manufacturing expenses [21][22] - G&A expenses for Q3 2025 were $52.8 million, compared to $24.0 million in Q3 2024, driven by personnel-related expenses and increased commercial preparation activities [21][22] - The net loss for Q3 2025 was $305.2 million, compared to $156.3 million in Q3 2024, attributed to higher operating expenses [21][22] - The company reiterated its 2025 financial guidance, expecting a full-year GAAP net loss between $1.03 billion and $1.09 billion [22] Business Line Data and Key Metrics Changes - Diraxonrasib, the company's lead product, has received three special designations from the FDA for its potential in treating pancreatic cancer, including breakthrough therapy status and orphan drug designation [4][5] - The phase 3 trial, Resolute 302, for Diraxonrasib in second-line metastatic pancreatic cancer is nearing completion of enrollment, with data readout expected in 2026 [7][9] - Initial results for Diraxonrasib in first-line metastatic pancreatic cancer showed an objective response rate of 47% and a disease control rate of 89% for monotherapy [8] - The combination of Diraxonrasib with standard chemotherapy (GMP) demonstrated an objective response rate of 55% and a disease control rate of 90% [8][9] Market Data and Key Metrics Changes - The company is expanding its clinical programs in non-small cell lung cancer (NSCLC) with ongoing trials for Diraxonrasib and Allieronrasib, targeting both previously treated and first-line metastatic settings [14][15] - The Resolve 301 registration trial for Diraxonrasib versus docetaxel in RAS mutant NSCLC continues to enroll patients in the U.S., Europe, and Japan [14] - The company is also evaluating Zoledronrasib in a phase 1 monotherapy expansion cohort for previously treated NSCLC [16] Company Strategy and Development Direction - The company aims to build a leading global franchise for RAS-targeted medicines, focusing on pancreatic, lung, and colorectal cancers [4][18] - There is a strong emphasis on advancing clinical trials and expanding partnerships to enhance treatment strategies for RAS-addicted cancers [18] - The company is committed to patient-friendly clinical protocols and educational initiatives, aligning with global awareness months for pancreatic and lung cancers [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of their RAS-on inhibitor portfolio to change standards of care across multiple cancer types [17] - The company is actively preparing for data readouts and NDA submissions, leveraging the FDA's National Priority Voucher to potentially accelerate review timelines [26][27] - Management highlighted the importance of ongoing collaborations to explore diverse treatment strategies and combinations [18] Other Important Information - The company has made key appointments to strengthen its R&D and commercialization capabilities, including a new Chief Development Officer and regional leaders for U.S. and European markets [18][19] - The company is exploring various combinations of RAS-on inhibitors with novel disease target inhibitors to expand treatment options [18] Q&A Session Summary Question: Impact of FDA Commissioner's National Priority Voucher on Diraxonrasib timelines - Management indicated that the voucher could potentially shorten review timelines by one to two months and they are preparing aggressively for data readout and NDA submission [26][27] Question: Rationale for randomizing against observation in Resolute 304 trial - Management explained that requiring four months of standard care chemotherapy is to ensure uniformity in the patient population and build upon the modest success seen with chemotherapy [30][32] Question: Expectations for phase 2 study results translating to phase 3 study - Management reassured that the patient populations in phase 1 and phase 3 studies are comparable, and they expect similar performance in the control arm based on historical data [39][40] Question: Commercial readiness and manufacturing capacity - Management confirmed strong organizational and supply chain capabilities to support product launch and emphasized ongoing preparations for commercialization readiness [41][42] Question: Efficacy of combination treatment versus monotherapy - Management highlighted that both treatment strategies are being tested to evaluate their potential benefits, with updates expected in the first half of 2026 [46][48] Question: Commercial opportunity in the European Union - Management expressed confidence in the market potential for Diraxonrasib in Europe, emphasizing the significant number of patients to treat and the compelling value proposition [68] Question: Rationale for starting the adjuvant study before the first-line study - Management clarified that the adjuvant study is simpler and could be initiated earlier, without significant implications for overall conduct [70]

On Target to Outsmart Cancer November 2025 © 2025 Revolution Medicines, Inc. 2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to manage existing collaborations and estab ...

Drug Development and Clinical Trials - The company is developing a pipeline of RAS(ON) inhibitors, including daraxonrasib, elironrasib, and zoldonrasib, targeting RAS-addicted cancers [111]. - Daraxonrasib has received Breakthrough Therapy Designation from the FDA for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) with KRAS G12 mutations [112]. - The ongoing RASolute 302 study is a Phase 3 trial comparing daraxonrasib (300 mg daily) to chemotherapy, with expected clinical readout in 2026 [113]. - Elironrasib has received Breakthrough Therapy Designation from the FDA for KRAS G12C-mutated locally advanced or metastatic NSCLC [124]. - The company plans to initiate a global Phase 3 trial of daraxonrasib in combination with pembrolizumab and chemotherapy in 2026 [116]. - Clinical data for daraxonrasib showed it was well tolerated and demonstrated encouraging antitumor activity in patients with RAS-mutant PDAC [117]. - The company is evaluating multiple combination regimens for daraxonrasib, including with pembrolizumab and standard chemotherapy agents [120]. - Zoldonrasib is designed to irreversibly inactivate RAS G12D and is currently in development [130]. - The company is advancing RMC-5127 (G12V) into clinical development, expanding its RAS(ON) inhibitor portfolio [111]. - The company is winding down enrollment for the RASolute 302 study as it nears completion at all sites [113]. - The company expects to initiate a registration trial for zoldonrasib combination therapy in first-line metastatic PDAC in the first half of 2026 [132]. - A first-in-human dose escalation clinical trial of RMC-5127 is expected to begin in Q1 2026 [134]. - The company plans to conduct additional pivotal combination studies in 2026 that incorporate either zoldonrasib or elironrasib [132]. - The company entered into a collaboration with Tango Therapeutics in November 2024 to investigate vopimetostat in combination with daraxonrasib and zoldonrasib [139]. Financial Performance - Research and development expenses for Q3 2025 were $262.5 million, an increase of 73% from $151.8 million in Q3 2024 [152]. - General and administrative expenses for Q3 2025 were $52.8 million, up 120% from $24.0 million in Q3 2024 [152]. - Total operating expenses for the nine months ended September 30, 2025, reached $820.7 million, a 73% increase compared to $473.2 million for the same period in 2024 [152]. - The net loss for Q3 2025 was $305.2 million, compared to a net loss of $156.3 million in Q3 2024, reflecting an increase of 95% [152]. - Interest income for Q3 2025 was $22.1 million, an increase from $20.4 million in Q3 2024 [152]. - Research and development expenses increased by $110.8 million, or 73%, during the three months ended September 30, 2025, compared to the same period in 2024, primarily due to higher clinical trial expenses for daraxonrasib [153]. - Total research and development expenses for the nine months ended September 30, 2025, were $692.4 million, an increase of $288.3 million, or 71%, compared to the same period in 2024 [154]. - General and administrative expenses rose by $28.8 million, or 120%, during the three months ended September 30, 2025, driven by increased commercial preparation and employee-related expenses [155]. - Interest income increased by $1.7 million during the three months ended September 30, 2025, due to a larger cash and marketable securities balance [157]. - Interest expense increased by $11.4 million during the three months ended September 30, 2025, primarily due to the Royalty Purchase Agreement [158]. - As of September 30, 2025, the company had $1.9 billion in cash, cash equivalents, and marketable securities [172]. - The company completed the EQRx Acquisition in November 2023, issuing 54,786,528 shares and receiving $1.1 billion in net cash [162]. - The company entered into a Royalty Purchase Agreement in June 2025, receiving an upfront payment of $250 million and the potential for an additional $1 billion in synthetic royalty funding [164]. - The company has an accumulated deficit of $2.5 billion as of September 30, 2025, with primary cash usage for research and development expenditures [173]. - The company expects expenses to continue to increase as it advances product candidates into later stages of development, including larger clinical trials [173]. - The company has cash, cash equivalents, and marketable securities totaling $1.9 billion as of September 30, 2025, down from $2.3 billion as of December 31, 2024 [191]. - Cash used in operating activities for the nine months ended September 30, 2025, was $623.5 million, attributed to a net loss of $766.4 million [177]. - Cash provided by investing activities for the nine months ended September 30, 2025, was $43.2 million, consisting of $1.5 billion in maturities of marketable securities [179]. - Cash provided by financing activities for the nine months ended September 30, 2025, included $244.2 million from the sale of future royalties [181]. - The company anticipates substantial additional funds will be required for development efforts and potential commercialization of current and future programs [175]. - The company may seek additional capital through various means, including public or private equity offerings and debt financings, depending on market conditions [175]. - Cash used in operating activities for the nine months ended September 30, 2024, was $419.1 million, with a net loss of $405.5 million [178]. - The company entered into a Royalty Purchase Agreement in June 2025, allowing Royalty Pharma to receive tiered royalty payments on worldwide net product sales of daraxonrasib and zoldonrasib [185]. - The company has contractual obligations related to office and laboratory space lease in Redwood City, California [183]. - The company is exposed to interest rate risk, but historical fluctuations in interest income have not been significant due to the short-term maturities of its cash equivalents and marketable securities [191].